Inhibition of tumor-intrinsic NAT10 enhances antitumor immunity by triggering type I interferon responses via MYC/CDK2/DNMT1 pathway.
Ontology highlight
ABSTRACT: Inhibition of tumor-intrinsic NAT10 enhances antitumor immunity by triggering type I interferon responses via MYC/CDK2/DNMT1 pathway.
PROVIDER: PRJNA1204289 | ENA |
REPOSITORIES: ENA
ACCESS DATA